ESMO Voices Deep Concern About Future of Cancer Research - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
ESMO Voices Deep Concern About Future of Cancer Research

Source: Applied Clinical Trials

The European Society for Medical Oncology (ESMO) is concerned that the proposed European Union General Data Protection Regulation could make cancer research impossible and add a significant burden to both doctors and cancer patients.

The proposed wording of the regulation stipulates “explicit and specific patient consent,” meaning that researchers would have to approach patients every time a study is planned in order to consult their data or use tissue samples stored for research purposes.

"This could put a halt to many public health research efforts," said ESMO President Rolf A. Stahel, who was the first President of the Swiss Society for Medical Oncology and was President of the Swiss Institute for Applied Cancer Research from 1999 to 2005.

ESMO proposes that the text of the EU regulation includes a one-time consent for research, ensuring patients are aware of what they are consenting to. This would help to guarantee the appropriate safeguards are in place and patients can withdraw their consent at any time.

"Our proposal achieves the correct balance between the right to privacy and the right to health," he said. "It actually 'empowers' patients, allowing them to choose whether to donate their data and tissue for public health research, whose ultimate goal is to find cures."

ESMO is in favor of the inclusion in the EU General Data Protection Regulation of the withdrawable 'one-time consent' concept [6] – already foreseen in the Clinical Trials Regulation [7] adopted by the European Union in 2014, which allows to use data already stored beyond the end and the specific scope of a trial, with the usual strict safeguards.

According to Stahel, "We are calling upon the European Union to assure that all forms of public health research will survive and be able to function within the safeguards that are in place, without adding the nearly impossible administrative burden of re-consenting each patient, every time, for every single project, which could irreversibly slow down the accelerated pace that cancer research has gained over the past decades."

Paolo G. Casali, ESMO’s Public Policy Committee Chair and author of the official ESMO Position Paper on the risks of the new Data Protection Regulation, added: “We understand the need for the EU to address data privacy concerns in many sectors, with the surge of risks brought about by the use of digital information, but its effect on public health research may have been unintentionally overlooked."

Population-based cancer registries, for example, storing information to monitor disease trends, are intrinsically incompatible with any requirement of individual consent. If a patient is allowed not to consent use of his/her anonymized data for the registry, the data provided by that registry will be unrepresentative and can lead to incorrect conclusions for public health actions, he explained.

Read the full release here.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here